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Abstract
Background: CHI3LI encoding the inflammatory glycoprotein YKL-40 is located on chromosome 1q32.1. YKL-40 is involved
in inflammatory processes and patients with Type 2 Diabetes (T2D) have elevated circulating YKL-40 levels which correlate
with their level of insulin resistance. Interestingly, it has been reported that rs10399931 (2329 G/A) of CHI3LI contributes to
the inter-individual plasma YKL-40 levels in patients with sarcoidosis, and that rs4950928 (2131 C/G) is a susceptibility
polymorphism for asthma and a decline in lung function. We hypothesized that single nucleotide polymorphisms (SNPs) or
haplotypes thereof the CHI3LI locus might influence risk of T2D. The aim of the present study was to investigate the putative
association between SNPs and haplotype blocks of CHI3LI and T2D and T2D related quantitative traits.
Methods/Principal Findings: Eleven SNPs of CHI3LI were genotyped in 6514 individuals from the Inter99 cohort and 2924
individuals from the outpatient clinic at Steno Diabetes Center. In cas-control studies a total of 2345 T2D patients and 5302
individuals with a normal glucose tolerance test were examined. We found no association between rs10399931 (OR, 0.98
(CI, 0.88–1.10), p=0.76), rs4950928 (0.98 (0.87–1.10), p=0.68) or any of the other SNPs with T2D. Similarly, we found no
significant association between any of the 11 tgSNPs and T2D related quantitative traits, all p.0.14. None of the identified
haplotype blocks of CHI3LI showed any association with T2D, all p.0.16.
Conclusions/Significance: None of the examined SNPs or haplotype blocks of CHI3LI showed any association with T2D or
T2D related quantitative traits. Estimates of insulin resistance and dysregulated glucose homeostasis in T2D do not seem to
be accounted for by the examined variations of CHI3LI.
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Introduction
The primary molecular defects in Type 2 diabetes (T2D) remain
largely unknown, but it is widely recognized that both genetic and
environmental risk factors have interacting roles in the pathogen-
esis and the progression of the disease. However, recent discoveries
have led to a progress in the understanding of the molecular
genetic background of T2D brought forward by genome-wide
association (GWA) studies which have dramatically increased the
number of validated type 2 diabetes loci with modest impact on
relative diabetes risk [1–3]. Several loci of interest may be located
in the region of human chromosone 1q21–24 which shows
replicated linkage to T2D in at least eight populations including
North European Caucasian families, Pima Indians and Old Order
Amish [1]. Furthermore, linkage analysis has also provided
evidence for linkage of the metabolic syndrome (central obesity,
dyslipidemia, hyperglycemia and hypertension) to 1q23–31 [4].
These regions as well as other closely related regions of
chromosome 1 are under intense search for identification of
T2D susceptibility genes.
Chitinase 3-like 1 (CHI3LI) encoding the inflammatory
glycoprotein YKL-40 is located in a phylogenetically highly
conserved area on chromosome 1q32.1. YKL-40 is involved in
inflammatory processes and extracellular matrix remodelling
including angiogenesis and functions as a growth factor for several
cell types [5]. Studies have shown, that patients with T2D have
elevated plasma YKL-40 levels [6,7] which correlate with insulin
resistance and with their diabetic lipid profile, but not with
estimates of glycemic regulation [6]. Also patients with type 1
diabetes (T1D) have elevated YKL-40 levels which increase with
increasing levels of albuminuria [8].
The CHI3LI promotor variant 2329 G/A (rs10399931)
associates with the inter-individual plasma YKL-40 levels in
patients with sarcoidosis [9]. Furthermore, the functional CHI3LI
promotor SNP 2131CRG (rs4950928) increases the mRNA
transcript levels coding for the YKL-40 protein in a genome wide
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lymphoblastoid cells from children with asthma [10] and is shown
to be predictive of asthma, bronchial hyperresponsiveness and
reduced lung function [11]. Since CHI3LI is a susceptibility gene
for asthma with elevated circulating YKL-40 levels as a biomarker,
it is possible that one of these single nucleotide polymorphisms
(SNPs) or another gene variation with which they could be in tight
linkage disequilibrium with may be functional in relation to T2D.
Applying a HapMap–based tgSNP approach the objective of
the present study was to investigate the putative association of
common variation in the CHI3LI locus with T2D, obesity and
several T2D associated quantitative traits.
Methods
Ethics Statement
Informed written consent was obtained from all participants
before participation. The study was approved by the Ethical
Committees of Copenhagen and Aarhus and was in accordance
with the principle of the Helsinki Declaration II.
Study population
A total of 11 tgSNPs (including the rs10399931 and rs4950928)
covering all haplotype blocks in CHI3LI locus was genotyped.
Genotyping was performed in 9438 individuals including Inter99,
a population-based sample of unrelated, middle-aged Danish
individuals living in the greater Copenhagen area, and 2924
individuals recruited from the outpatient clinic at Steno Diabetes
Center.
The Inter99 study population has been described in detail
previously [12]. In brief, both participants from the Inter99 cohort
and individuals recruited from the outpatient clinic were
characterized by an oral glucose tolerance test (OGTT). Impaired
glucose homeostasis (IFG, IGT and diabetes) was defined
according to WHO criteria after a 75 g OGTT [13] giving a
classification of normal glucose tolerance (NGT; n=5302),
impaired fasting glycemia (IFG; n=540), impaired glucose
tolerance (IGT; n=830) or screen-detected untreated T2D
(SDU DM; n=294). Missing data was seen in 421 individuals
(4.5%) and a total of 2091 individuals had known T2D. The
participants were investigated for an association between genotype
and quantitative metabolic traits; individuals with known type 2
diabetes were excluded from these analyses. All participants were
of Danish nationality.
Biochemical and anthropometric measurements
Height and body weight were measured in light indoor clothes
and without shoes, and BMI was calculated as weight (kg) divided
by (height (m))
2. Waist circumference was measured in the
standing position midway between the iliac crest and the lower
costal margin and hip circumference at its maximum.
In both Inter99- and Steno Diabetes Center participants, blood
samples were drawn in the fasting state after a 12-h overnight fast.
Plasma glucose was analysed by a glucose oxidase method
(Granutest, Merck, Darmstadt, Germany). HbA1C was measured
by ion-exchange high performance liquid chromatography
(normal reference range: 4.1–6.4%) and serum insulin (excluding
des(31, 32) and intact proinsulin) was measured using the
AutoDELFIA insulin kit (Perkin-Elmer/Wallac, Turku, Finland).
Serum C-peptide concentrations were measured by a time-
resolved fluoroimmunoassay (AutoDELFIA C-peptide kit; Per-
kin-Elmer/Wallac, Turku, Finland).
Serum triglyceride and total and HDL-cholesterol were
analysed using enzymatic colorimetric methods (GPO-PAP and
CHOD-PAP, Roche Molecular Biochemicals, Mannheim, Ger-
many). HOMA-IR was calculated as fasting plasma glucose
[mmol/l] multiplied by fasting serum insulin [pmol/l] and divided
by 22.5. Insulinogenic index at 30 min was calculated as fasting
serum insulin subtracted from plasma insulin at 30 min [pmol/l]
divided by plasma glucose at 30 min [mmol/l].
Genotyping
SNPs in a region 22 kb upstream and 10 kb downstream of
CHI3LI were chosen from the HapMap project (www.hapmap.
org). Haplotype tgSNPs were selected from the HapMap data
using TAGGER [14]. TAGGER was used with a 5% MAF cut
off, agressive tagging (r
2.0.8). Two haplotype blocks with 2 and 5
SNPs, respectively, and with similar structures in both patients
with T2D and in controls were identified (Figure 1). The other
tgSNPs were not included in the haplotype block analyses since
they were not part of any block. Genotyping was performed using
TaqMan allelic discrimination (Kbioscience, Herts, UK) with a
success rate .97.0%. Discordance was 0% as judged from re-
genotyping of 965 random duplicate samples. Genotype distribu-
tion obeyed Hardy Weinberg Equilibrium (HWE), all p.0.25.
Statistical analyses
Logistic regression analyses were used to analyse differences in
allele and genotype frequencies between case and control subjects;
analyses were adjusted for age, sex and BMI where appropriate.
The statistical analyses were performed using RGui version 2.5.0
(available at http://www.r-project.org). The haplotype block
analyses were analysed for an association with T2D after
adjustment for age, sex and BMI. Haplotype analyses were
performed using PLINK [15]. P-values are not adjusted for
multiple testing.
Results
Clinical characteristics for the Inter99 cohort and the
individuals recruited at Steno Diabetes Center are presented in
Table 1. A total of 2345 T2D patients and 5302 individuals with a
normal glucose tolerance test were identified.
Overall we found no association of rs10399931, rs4950928 or
any of the other tgSNPs of CHI3LI with T2D after adjustment for
age, sex, BMI and glucose tolerance, all p.0.25 (Table 2). In
similar analyses, none of the tgSNPs were associated with impaired
fasting glucose (IFG) or impaired glucose tolerance (IGT),
although a borderline protective association with IGT was
detected for rs12123883 (Table S1 and S2).
Table 3 and 4 show the multiadjusted association of rs10399931
and rs4950928 with BMI and other T2D related quantitative traits
among NGT, IFG, IGT and screen-detected untreated T2D in
Inter99 and Steno Diabetes Center collected individuals. We
found a significant association between rs10399931 and the serum
C-peptide concentration after 2 hours, p=0.03, but in all we
found no significant association between rs10399931 or rs4950928
and any of the T2D quantitative traits. Similarly, none of the other
SNPs showed any associations (data not shown).
The two identified haplotype blocks of CHI3LI did not show any
association with T2D (Table 5).
Discussion
This is a large-scale and to our knowledge the first study of
variation in CHI3LI in relation to T2D and pre-diabetic
quantitative traits. CHI3LI encodes the inflammatory protein
YKL-40 which previously has been found to be elevated in plasma
YKL-40 in Type 2 Diabetes
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also correlates with increasing levels of albuminuria [8]. In our
study, we have exmained 11 tgSNPs covering the common
variation (MAF.5%) in CHI3LI including the SNPs rs10399931
and rs4950928 which previously have been found to contribute to
interindividual variations in circulating YKL-40 levels in patients
with sarcoidosis [9] and asthma [11], respectively. Furthermore,
CHI3LI has been found to be a susceptibility gene for asthma,
since rs4950928 is predictive of asthma, bronchial hyperrespon-
siveness and reduced lung function.
A total of 9438 individuals have been examined, but no
significant association of rs10399931, rs4950928 or any of the
other tgSNPs of CHI3LI were found with T2D or any of the
intermediate T2D related quantitative traits. A borderline
protective association with IGT was detected for rs12123883,
but rs12123883 is a rare SNP with only few homozygotes and the
protective association is most likely a chance finding. Furthermore,
the p-value would not withstand correction for multiple testing
considering the number of tests performed. On the same line,
none of the two identified haplotype blocks showed any association
with T2D.
In association analyses of rs10399931 and SNPs analysed in the
DGI genome wide association scan study, rs10399931 is in LD
with rs4950929 (r
2=0.74) and rs946263 (r
2=0.78). Other
correlations had r
2-values,0.05. In the DGI genome wide
association scan study, no significant associations of rs4950929
with any of the type 2 diabetic phenotypic traits were found, but
the rs946263 G-allele was nominally found to be associated with
T2D (p=0.027) [16]. rs946263, which is a synonymous SNP
located 29639 base pairs from the translational start site in
Figure 1. Linkage disequilibrium (LD) pattern of the investigated variations of CHI3L1.
doi:10.1371/journal.pone.0005469.g001
Table 1. Clinical data for study sample.
Complete sample SDC sample Inter99 cohort
N (m/w) 9438 (4834/4604) 2924 (1665/1259) 6514 (3169/3345)
NGT 5302 (2456/2846) 734 (334/400) 4568 (2122/2446)
IFG 540 (391/149) 32 (18/14) 508 (373/135)
IGT 830 (414/416) 123 (66/57) 707 (348/359)
SDU DM 294 (187/107) 39 (27/12) 255 (160/95)
Known DM 2051 (1259/801) 1946 (1200/755) 105 (59/46)
NGT age (years) 47695 8 694 5 68
NGT BMI (kg/m
2) 25.669.1 25.968.7 25.564.1
T2D age (years) 60612 62611 5167
T2D BMI (kg/m
2) 30.165.5 30.065.5 30.465.6
T2D HbA1c (%) 7.861.7 8.161.6 7.161.7
Data is mean6S.D. SDC, Steno Diabetes Center; N (m/w), number (men/
women); NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT,
impaired glucose tolerance; SDU DM, screen detected untreated diabetes
mellitus; T2D, Type 2 diabetes; BMI, Body Mass Index; HbA1c, hemoglobin A1c.
doi:10.1371/journal.pone.0005469.t001
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2=1.0) with rs4950928, which
accounts for approximately 10% of the variance in plasma YKL-
40 levels in asthma patients [11]. Beside the LD of rs10399931 and
rs4950928 with rs946263, none of the examined SNPs or
haplotype blocks of CHI3LI seem to be of any significance for
the T2D diagnosis or any of the T2D related quantitative traits.
Since the encoded inflammatory protein, YKL-40, of CHI3LI
seems to be both a marker of inflammation and endothelial
dysfunction [5,17] it is possible that it is the endothelial
dysfunction and the later micro- and macrovascular complications
of T2D that accounts for the elevated YKL-40 levels in T2D
patients. In endothelial dysfunction, elevated YKL-40 levels seem
to play a role in relation to cell migration, reorganization and
tissue remodelling as a response to endothelial damage [18–20].
The possible assocation between YKL-40 and vascular damage
is supported by the finding of an independent association between
elevated circulating YKL-40 levels and increasing levels of
albuminuria in T1D patients [8]. Elevated plasma YKL-40 is
also found to be associated with the presence and extent of
coronary artery disease as assessed by coronary angiography [21]
and just recently, YKL-40 levels have been found to be elevated in
patients with myocardial infarction [22]. Furthermore, increasing
YKL-40 levels do predict cardiovascular mortality in individuals
without known DM or CHD after adjustment for known CV risk
factors and markers [7].
Substantial evidence supports the notion that endothelial
dysfunction and low-grade inflammation play a major pathophys-
iological role in the development of insulin resistance and the
Table 2. Case control association studies of 2345 T2D patients and 5302 glucose tolerant control participants in relation to the 11
tgSNPs of CHI3LI.
SNP Allele MAF Genotype Genotype distribution Additive model p value
(major/minor) (%) All NGT, n (%) T2D, n (%) OR (CI)
rs883125 C/G 15.6 CC 3546 (71.8) 1574 (71.0) 0.98 (0.86–1.12) 0.78
CG 1280 (25.9) 591 (26.7)
GG 114 (2.3) 51 (2.3)
rs880633 C/T 46.3 CC 1470 (30.0) 645 (29.4) 1.00 (0.90–1.10) 0.96
CT 2416 (49.3) 1077 (48.8)
TT 1018 (20.7) 483 (21.8)
rs4950928 C/G 20.4 CC 3159 (63.6) 1402 (63.4) 0.98 (0.87–1.10) 0.68
CG 1612 (32.4) 716 (32.4)
GG 197 (4.0) 93 (4.2)
rs10399931 C/T 23.7 CC 2894 (58.8) 1287 (58.4) 0.98 (0.88–1.10) 0.76
CT 1754 (35.6) 791 (35.9)
TT 273 (5.6) 126 (5.7)
rs6691378 G/A 12.6 GG 3840 (77.7) 1690 (76.4) 1.08 (0.94–1.25) 0.29
GA 1030 (20.9) 487 (22.0)
AA 69 (1.4) 34 (1.6)
rs4950930 G/A 4.0 GG 4512 (91.6) 2053 (92.5) 0.96 (0.76–1.20) 0.70
GA 399 (8.1) 157 (7.1)
AA 13 (0.3) 10 (0.5)
rs12123883 T/C 7.4 TT 4235 (85.5) 1906 (85.7) 0.95 (0.79–1.14) 0.58
TC 684 (13.8) 305 (13.7)
CC 37 (0.7) 13 (5.8)
rs2486064 G/A 42.3 GG 1636 (33.0) 742 (33.7) 0.97 (0.87–1.07) 0.48
GA 2406 (48.6) 1057 (48.0)
AA 909 (18.4) 402 (18.3)
rs2886117 G/A 12.9 GG 3809 (76.6) 1679 (75.8) 1.04 (0.90–1.20) 0.59
GA 1078 (21.7) 500 (22.6)
AA 84 (1.7) 36 (1.6)
rs872129 A/G 7.2 AA 4183 (84.5) 1910 (86.1) 0.91 (0.76–1.09) 0.32
AG 730 (14.8) 298 (13.4)
GG 35 (0.7) 11 (0.5)
rs871799 G/C 9.2 GG 4028 (81.3) 1821 (82.3) 0.96 (0.81–1.13) 0.60
GC 873 (17.6) 376 (17.0)
CC 54 (1.1) 16 (0.7)
T2D, type 2 diabetes; SNP, single nucleotide polymorphism; MAF, minor allele frequency; NGT, normal glucose tolerance; OR (CI), odds ratio (confidence interval).
doi:10.1371/journal.pone.0005469.t002
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that YKL-40 levels are elevated in patients with T2D where it
correlates with insulin resistance as assessed by the HOMA model
and with levels of triglycerides and non-esterified fatty acids [6].
Since we found no association of any of the tgSNPs and surrogate
markers of insulin resistance or the diabetic lipid profile in the
present study, it does not seem to be any of these tgSNPs that
explain the previously found correlation with these variables [6].
Multiple genes on different chromosomes may influence
inflammatory biomarker levels and may have a potential role in
the development of insulin resistance through a low-grade
inflammatory state [30–33]. In proximity of the YKL-40 encoding
gene, locus 1q32.2 has been documented to influence the plasma
levels of ICAM-1[30], an adhesion molecule well-documented to
participate in endothelial dysfunction and the development of T2D
[23,25]. However, association studies between YKL-40 and ICAM-
1, either at protein or transcript levels, have not been conducted.
Neither have association studies of variations of CHI3L1 in relation
to micro- or macrovascular conditions never been made.
In conclusion, both rs10399931 and rs4950928 are in high LD
with rs946263 which is reported to associate with phenotypic traits
of T2D in DGI [16]. However, neither rs1039991 nor rs4950928
nor any other tgSNPs of CHI3LI which were investigated in the
present study are associated with T2D or T2D related quantitative
traits including estimates of insulin resistance and dysregulated
glucose homeostasis in the examined approximately 9500 Danes.
Further studies are required to determine YKL-40 levels as a
marker of inflammation in the prediabetic state and the role of
CHI3LI in the pathogenesis of T2D.
Supporting Information
Table S1 Case control association studies of 540 individuals with
impaired fasting glucose (IFG) and 5302 glucose tolerant control
participants in relation to the 11 tgSNPs of CHI3LI.
Found at: doi:10.1371/journal.pone.0005469.s001 (0.08 MB
DOC)
Table S2 Case control association studies of 830 individuals with
impaired glucose tolerance (IGT) and 5302 glucose tolerant
control participants in relation to the 11 tgSNPs of CHI3LI
Found at: doi:10.1371/journal.pone.0005469.s002 (0.08 MB
DOC)
Table 3. Association of rs10399931 of CHI3LI and T2D related
quantitative traits among NGT, IFG, IGT and screen-detected
untreated T2D in Inter99 and Steno Diabetes Center collected
individuals.
Genotype CC CT TT Padd
Alleles 4782 2927 781
Age (years) 46684 6 684 6 68
BMI (kg/m
2) 26.264.5 26.264.6 25.964 0.75
Whratio 0.8660.09 0.8660.09 0.8660.09 0.89
Waist (cm) 87613 87613 86613 0.69
Height (cm) 17269 17269 17269 0.47
Fasting serum triglyceride (mmol/l) 1.361.5 1.361.1 1.360.8 0.75
Fasting serum cholesterol (mmol/l) 5.661.1 5.661.1 5.661.1 0.61
Fasting serum HDL cholesterol
(mmol/l)
1.460.4 1.460.4 1.460.4 0.44
Systolic bp (mmHg) 130617 131617 131617 0.41
Diastolic bp (mmHg) 82611 83611 82612 0.34
Fasting plasma insulin (pmol/l) 42628 42627 41627 0.98
Plasma insulin 30 min (pmol/l) 2936191 2886175 2856169 0.94
Plasma insulin 120 min (pmol/l) 2176217 2156203 2246208 0.16
HOMA-IR 10.668.1 10.567.7 10.467.7 0.95
Insulinogenic Index 30620 29619 29618 0.75
Fasting plasma glucose (mmol/l) 5.560.8 5.560.9 5.560.7 0.84
Plasma glucose 30 min (mmol/l) 8.761.9 8.761.9 8.761.8 0.44
Plasma glucose 120 min (mmol/l) 6.262.2 6.262.2 6.362.1 0.71
Fasting plasma C-peptide (pmol/l) 5966274 5936256 5946273 0.53
Plasma C-peptide 30 min(pmol/l) 20066736 19946678 19776732 0.86
Plasma C-peptide 120 min (pmol/l) 230561041 23156980 23596987 0.03
Data presented as mean (SD). Analyses adjusted for age, gender, BMI, glucose
tolerance (NGT, IFG, IGT and screen-detected untreated T2D).
T2D, type 2 diabetes; NGT, normal glucose tolerance; IFG, impaired fasting
glucose; IGT, impaired glucose tolerance; add, additive; dom, dominant; res,
recessive; bmi, body mass index; whratio, waist-to-hip ratio; hdl, high density
lipoprotein; bp, blood pressure; HOMA-IR, insulin resistance according to HOMA
model.
doi:10.1371/journal.pone.0005469.t003
Table 4. Association of rs49509028 of CHI3LI and T2D related
quantitative traits among NGT, IFG, IGT and screen-detected
untreated T2D in Inter99 and Steno Diabetes Center collected
individuals.
Genotype CC CG GG Padd
Alleles 5172 2635 334
Age (years) 46684 6 684 6 68
BMI (kg/m
2) 26.264.5 26.164.6 25.863.8 0.14
Whratio 0.8660.09 0.8660.09 0.8660.09 0.43
waist (cm) 87613 86613 86612 0.56
Height (cm) 172691 7 2 691 7 2 69 0.91
Fasting serum triglyceride (mmol/l) 1.361.4 1.361.1 1.360.9 0.85
Fasting serum cholesterol (mmol/l) 5.661.1 5.661.1 5.661.1 0.28
Fasting serum HDL cholesterol
(mmol/l)
1.460.4 1.460.4 1.460.4 0.36
Systolic bp (mmHg) 130617 131617 130617 0.53
Diastolic bp (mmHg) 82611 83611 82611 0.72
Fasting plasma insulin (pmol/l) 42628 41627 41625 0.35
Plasma insulin 30 min (pmol/l) 2956191 2876174 2766151 0.36
Plasma insulin 120 min (pmol/l) 2186215 2156216 2176191 0.54
HOMA-IR 10.667.9 10.467.8 10.166.8 0.47
Insulinogenic Index 30620 29619 28617 0.41
Fasting plasma glucose (mmol/l) 5.560.8 5.560.9 5.560.7 0.54
Plasma glucose 30 min (mmol/l) 8.761.9 8.761.8 8.761.8 0.94
Plasma glucose 120 min (mmol/l) 6.262.1 6.262.2 6.362.2 0.52
Fasting plasma C-peptide (pmol/l) 5976276 5866253 5916267 0.85
Plasma C-peptide 30 min(pmol/l) 20146738 19886676 19456709 0.54
Plasma C-peptide 120 min (pmol/l) 231461042 23016982 23366968 0.17
Data presented as mean (SD). Analyses adjusted for age, gender, BMI, glucose
tolerance (NGT, IFG, IGT and screen-detected untreated T2D).
T2D, type 2 diabetes; NGT, normal glucose tolerance; IFG, impaired fasting
glucose; IGT, impaired glucose tolerance; add, additive; dom, dominant; res,
recessive; bmi, body mass index; whratio, waist-to-hip ratio; hdl, high density
lipoprotein; bp, blood pressure; HOMA-IR, insulin resistance according to HOMA
model.
doi:10.1371/journal.pone.0005469.t004
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